Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_3
1
17%
Ph phase_4
5
83%

Phase Distribution

0

Early Stage

0

Mid Stage

6

Late Stage

Phase Distribution6 total trials
Phase 3Large-scale testing
1(16.7%)
Phase 4Post-market surveillance
5(83.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(2)
Terminated(1)
Other(2)

Detailed Status

Completed2
unknown2
Terminated1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 31 (16.7%)
Phase 45 (83.3%)

Trials by Status

completed233%
terminated117%
enrolling_by_invitation117%
unknown233%

Recent Activity

0 active trials
Showing 5 of 6
enrolling_by_invitationphase_4

Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus Combined With Metabolic Dysfunction-associated Steatotic Liver Disease

NCT07274644
unknownphase_4

Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes

NCT04893148
unknownphase_4

INSULIN THERAPY DE-INTENSIFICATION WITH iGlarLixi

NCT04945070
completedphase_3

Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi

NCT03130426
completedphase_4

Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)

NCT04196231
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07274644Phase 4

Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus Combined With Metabolic Dysfunction-associated Steatotic Liver Disease

Enrolling By Invitation
NCT04893148Phase 4

Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes

Unknown
NCT04945070Phase 4

INSULIN THERAPY DE-INTENSIFICATION WITH iGlarLixi

Unknown
NCT03130426Phase 3

Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi

Completed
NCT04196231Phase 4

Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)

Completed
NCT03881995Phase 4

Effects of Insulin Glargine and Lixisenatide on the Brain

Terminated

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6